NO910923L - Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel. - Google Patents

Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.

Info

Publication number
NO910923L
NO910923L NO91910923A NO910923A NO910923L NO 910923 L NO910923 L NO 910923L NO 91910923 A NO91910923 A NO 91910923A NO 910923 A NO910923 A NO 910923A NO 910923 L NO910923 L NO 910923L
Authority
NO
Norway
Prior art keywords
therapeutic agent
similar compound
trifunctional antibody
combined diagnostic
antibody similar
Prior art date
Application number
NO91910923A
Other languages
English (en)
Norwegian (no)
Other versions
NO910923D0 (no
Inventor
Clarence Ahlem
Ann E Huang
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of NO910923D0 publication Critical patent/NO910923D0/no
Publication of NO910923L publication Critical patent/NO910923L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO91910923A 1990-03-09 1991-03-08 Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel. NO910923L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49140690A 1990-03-09 1990-03-09

Publications (2)

Publication Number Publication Date
NO910923D0 NO910923D0 (no) 1991-03-08
NO910923L true NO910923L (no) 1991-09-10

Family

ID=23952086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91910923A NO910923L (no) 1990-03-09 1991-03-08 Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.

Country Status (7)

Country Link
EP (1) EP0453082A1 (de)
JP (1) JPH0692873A (de)
AU (1) AU637202B2 (de)
CA (1) CA2037835A1 (de)
IL (1) IL97459A0 (de)
NO (1) NO910923L (de)
ZA (1) ZA911741B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230525T2 (de) * 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5552525A (en) * 1991-02-08 1996-09-03 Diatech Inc. Technetium-99m labeled peptides for imaging inflammation
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
EP0596011A1 (de) * 1991-07-19 1994-05-11 Hybritech Incorporated Trifunktionelle verbindungen mit spezifizitaet fuer multi-drug resistente zellen
DK0720621T3 (da) * 1992-01-14 2001-08-06 Diatide Inc Radiomærkede somatostation-afledte peptider til billeddannende og terapeutiske anvendelser
US5989519A (en) * 1992-03-13 1999-11-23 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
US5508020A (en) * 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
EP0641222B1 (de) * 1992-05-21 2000-09-06 Diatide, Inc. Technetium-99m markierte peptide zur bilderzeugung von thrombus
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5871711A (en) * 1992-06-23 1999-02-16 Diatide, Inc. Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) * 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
GB2286189A (en) * 1992-10-15 1995-08-09 Scotgen Ltd Recombinant specific binding protein
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US6056940A (en) * 1993-04-08 2000-05-02 Diatide, Inc. Radiolabeled compounds for thrombus imaging
US5951964A (en) * 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US6051206A (en) * 1994-06-03 2000-04-18 Diatide, Inc Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
WO1998004592A1 (de) * 1996-07-25 1998-02-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vereinfachte herstellung bispezifischer antikörperfragmente
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
RU2149023C1 (ru) * 1998-04-20 2000-05-20 Ерхов Валентин Сергеевич Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP1419786A1 (de) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Verfahren zur quantitativen und selektiven Funktionalisierung von Immunoglobulin-Fab-Fragmenten, deren Konjugate und deren Zusammensetzungen
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
JP6423804B2 (ja) * 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
US12098215B2 (en) 2016-06-06 2024-09-24 Northwestern University Fusion protein construct
WO2018027223A1 (en) 2016-08-05 2018-02-08 Duke University Camkk2 inhibitor compositions and methods of using the same
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
WO2019183131A1 (en) 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
US12428626B2 (en) 2018-11-20 2025-09-30 Bioventures, Llc Cells for the production of viruses and methods of using the same
CA3229448A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2025240781A2 (en) 2024-05-15 2025-11-20 Werewolf Therapeutics, Inc. Modified antibodies and immunoglobulin formats
WO2026042012A1 (en) 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Single domain antibodies and polypeptides containing same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1260827A (en) * 1984-08-31 1989-09-26 Richard C. Siegel Antibody-metal ion complexes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
PT86377B (pt) * 1986-12-24 1990-11-20 Lilly Co Eli Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody

Also Published As

Publication number Publication date
AU7272291A (en) 1991-09-12
NO910923D0 (no) 1991-03-08
CA2037835A1 (en) 1991-09-10
EP0453082A1 (de) 1991-10-23
IL97459A0 (en) 1992-06-21
JPH0692873A (ja) 1994-04-05
AU637202B2 (en) 1993-05-20
ZA911741B (en) 1992-11-25

Similar Documents

Publication Publication Date Title
NO910923L (no) Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.
FI910851A7 (fi) 3-arylkarbonyl-1h-indoler anvaendbara som terapeutiska aemnen.
MX9102473A (es) Agentes farmaceuticos.
FI914619A7 (fi) Hydroxylfunktionaliserade polyeteraminer som barriaerfoerpackning foer syrekaensliga materialer.
FI914796L (fi) Omaettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI914596L (fi) Biaxialt orienterad polypropylenfolie avsedd som foerpackningsomslag.
FI884924L (fi) Humanimmuglobulin som producerats med hybrid-dna-teknik.
FI910993A7 (fi) Hjaelpmedel som foerbaettrar glidegenskaper.
DE59100682D1 (de) Atemschutzmaske.
FI914797L (fi) Maettade hydroxialkylkinolinsyror som leukotrienantagonister.
DE3889062D1 (de) Monoklonaler Antikörper gegen humanen BCDF.
FI912468L (fi) Oxidantkaensliga och -okaensliga aromatiska estrar som inhibitorer foer humant neutrofilelastas.
FI910572A7 (fi) Regnmaetare med anordning som paovisar tilltaeppning.
FI915568A0 (fi) Polyamidhartskompositioner foer anvaendning som bindemedel foer laminerande tryckfaergshartser.
FI923367L (fi) Molekyler med antikroppkombinations- staellen som katalyserar hydrolysreaktioner.
FI914795L (fi) Hydroxialkylkinolinetersyror som leukotrienantagonister.
NO890096D0 (no) Pyrazol- og indozolpyridinaminer, en fremgangsmaate for fremstilling og anvendelse derav som medikamenter.
FI923486A0 (fi) Terapeutiska aemnen.
NO893474L (no) Flammehemmende midler og fremgangsmaate for anvendelse.
NO901169L (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.
DE59104786D1 (de) Patientenliegefläche.
FR2713479B1 (fr) Bassin médical.
FI910753L (fi) Terapeutiska nukleocider.
FI923528A0 (fi) Terapeutiska aemnen.
NO901200D0 (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.